Abstract: Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.
Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
Abstract: The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits PDGF-stimulated smooth muscle cell proliferation or migration. In some embodiments, the atherosclerosis is associated with coronary artery disease, aneurysm, arteriosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification or inflammation. In some embodiments, the compound lowers low-density lipoprotein (LDL) cholesterol in the subject. In some embodiments, the compound maintains a normal low-density lipoprotein (LDL) cholesterol level in the subject.
Abstract: The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g. cancer.
Abstract: The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a FXR mediated disease or condition, such as NAFLD and NASH, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity.
Abstract: The invention relates to the field of therapy, in particular dermatology. Inventors herein identify for the first time inhibitors of matrix metalloproteinase-9 (MMP9) as active molecules for use for preventing, treating or alleviating skin depigmenting disorders in a subject in need thereof, and describe compositions and kits comprising such inhibitors as well as uses thereof. Inventors further describe a method for screening pharmaceutically active molecules suitable for preventing, treating or alleviating a depigmenting disorder as well as methods for evaluating the efficacy of a depigmenting disorder treatment involving an inhibitor of MMP9 or for monitoring the course of depigmenting disorder in a subject exposed to such a treatment.
December 15, 2017
Date of Patent:
January 19, 2021
UNIVERSITÉ DE BORDEAUX, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX
Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia.
Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.
July 17, 2019
Date of Patent:
January 5, 2021
Xin Chen, Maiko C. Hermsmeier, Diana Lac, Douglas W. Thomas, Noymi Yam, Akira Yamamoto
Abstract: Ketone supplementation, such as through use of precursors of beta-hydroxybutyrate (BHB) and acetoacetate (AcAc), increased blood levels of ketone bodies, increases blood flow and wound closure in ischemic young and aged fisher rats significantly earlier compared to standard diet in aged rats. In vitro experiments with ketone bodies demonstrate decreased mitochondrial and cytosolic ROS in young and aged primary human dermal fibroblasts (PHDF). Ketone bodies increased migration in young and aged PHDFs.
Abstract: This invention pertains to an anti-microbial, in particular anti-bacterial and/or anti-fungal composition comprising cinnamaldehyde, trans-2-methoxycinnamaldehyde, cinnamyl acetate and linalool. In particular this composition is intended for preventing and/or treating microbial infection in an animal.
Abstract: This invention discloses applications of desogestrel in the preparation of anti-colon cancer/breast cancer ER-negative Ah receptor-positive products. This invention provides applications for desogestrel in the preparation of products to treat colon cancer and/or breast cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug desogestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that desogestrel has a new use as an anti-colon cancer medication, thus achieving a new purpose for an old drug.
Abstract: The present invention relates to a food composition and a pharmaceutical comprising D-tryptophan. The present invention further relates to D-tryptophan for use in the treatment, prevention or amelioration of a diseases associated with Treg or TH2 cells, such as allergy and in particular asthma.
September 19, 2017
Date of Patent:
December 8, 2020
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Susanne Krauss-Etschmann, Anton Hartmann, Philippe Schmitt-Kopplin, Michael Schloter
Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
Abstract: The present invention relates to methods for treating cell proliferation disorders comprising: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated; (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder; and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell prolifer
Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
Abstract: A method of treating or preventing a neuroinflammatory and/or neurodegenerative disease in a subject by administering a pharmaceutically effective amount of a CB2 receptor agonist is described. The CB2 receptor agonist can be a compound according to formula I (structurally represented) or a pharmaceutically acceptable salt thereof, with R1 and R2 functional groups as defined herein. Administration of the CB2 receptor agonist activates CB2 receptors in the microglia, and can restore synaptic plasticity, cognition, and memory in subjects having elevated levels of amyloid-13 peptide in the brain.